CKK will buy a minimum number of hyperthermia systems from BSD each year, as part of the agreement.
BSD Medical said it will initially focus on the regulatory approval and distribution of its BSD-500 Hyperthermia System and then expand distribution of BSD-2000 Hyperthermia System.
The BSD-500 System delivers noninvasive (external) hyperthermia by using antennas placed over the tumor or interstitial hyperthermia, which is delivered using antennas that are inserted into the tumor, or a combination of both.
The BSD-2000 delivers localized therapeutic heating using radiofrequency (RF) energy and creates energy which can be used electronically to focus the target’s shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region.
BSD Medical president Harold Wolcott said the receipt of the HDE marketing approval for the BSD-2000 will expand the market in Asia for BSD’s hyperthermia products.
